Company intelligence / Profile preview

Ori Scientific

London, England, United Kingdomoriscientific.au ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Ori Biotech has developed and launched IRO®, a next-generation automated, closed, and digitized cell and gene therapy manufacturing platform. It enables seamless scaling from preclinical process development to GMP/commercial-scale production. The system reduces labor by up to 70%, cost of goods by up to 50%, processing times by up to 25%, and accelerates tech transfer timelines from months to weeks. Over five years, best-in-class biological data were generated from over 500 runs with ten different partners across various cell types/protocols.

Modalities: Cell therapyGene therapy
Industry: Non-Drug Biotech

Partnerships

Multiple undisclosed industry partners through Early Access Program (LEAP)

Beyond the preview

Go deeper on Ori Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ori Scientific.

Explore the full profile